We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma

News   Jan 09, 2012

 
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair™* in COPD and Asthma
 
 
Advertisement
 

RELATED ARTICLES

FDA Grants Fast Track Designation to Onvansertib for Second-line Treatment of KRAS-mutated Colorectal Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

READ MORE

Trial Investigates Remdesivir–Baricitinib Combo as COVID-19 Treatment

News

Following on from remdesivir’s promising results from previous studies, a new trial is now investigating remdesivir in combination with baricitinib or placebo as a treatment for COVID-19, in a double-blind, randomized trial.

READ MORE

Anti-malarial Drug Shows Potential as Brain Cancer Treatment in Preclinical Models

News

In vitro studies have uncovered new insights that could help increase the effectiveness of the most common current treatments with the addition of lumefantrine, an FDA-approved drug used to treat malaria.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE